Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR

被引：4
作者：
Kaplan, David E. [1 ,2 ]
机构：
[1] Univ Penn, Perelman Sch Med, Div Gastroenterol, PCAM 7th Floor,3400 Civ Ctr Dr, Philadelphia, PA 19104 USA
[2] Corporal Michael J Crescenz VA Med Ctr, Gastroenterol Sect, Philadelphia, PA 19104 USA
来源：
DIGESTIVE DISEASES AND SCIENCES | 2018年 / 63卷 / 06期
关键词：
GENOTYPE; 1; INFECTION; COST-EFFECTIVENESS; UNITED-STATES; BOCEPREVIR; REGIMENS; THERAPY;
D O I：
10.1007/s10620-018-5014-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1376 / 1377
页数：2
相关论文
共 10 条
  • [1] Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Cabibbo, Giuseppe
    Ruggeri, Matteo
    Enea, Marco
    Bruno, Raffaele
    Capursi, Vincenza
    Gasbarrini, Antonio
    Alberti, Alfredo
    Craxi, Antonio
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (04) : 658 - 666
  • [2] Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving
    Chhatwal, Jagpreet
    He, Tianhua
    Hur, Chin
    Lopez-Olivo, Maria A.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (06) : 827 - +
  • [3] Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States
    Chhatwal, Jagpreet
    Ferrante, Shannon A.
    Brass, Cliff
    El Khoury, Antoine C.
    Burroughs, Margaret
    Bacon, Bruce
    Esteban-Mur, Rafael
    Elbasha, Elamin H.
    [J]. VALUE IN HEALTH, 2013, 16 (06) : 973 - 986
  • [4] Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease
    Gordon, S. C.
    Hamzeh, F. M.
    Pockros, P. J.
    Hoop, R. S.
    Buikema, A. R.
    Korner, E. J.
    Terrault, N. A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (07) : 784 - 793
  • [5] Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort
    Maier, Marissa M.
    Zhou, Xiao-Hua
    Chapko, Michael
    Leipertz, Steven L.
    Wang, Xuan
    Beste, Lauren A.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (06) : 1454 - 1462
  • [6] The Effect of Hepatitis C Treatment Response on Medical Costs: A Longitudinal Analysis in an Integrated Care Setting
    Manos, M. Michele
    Darbinian, Jeanne
    Rubin, Jaime
    Ray, G. Thomas
    Shvachko, Valentina
    Denis, Bans
    Velez, Fulton
    Quesenberry, Charles
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2013, 19 (06): : 438 - 447
  • [7] Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
    Petta, Salvatore
    Cabibbo, Giuseppe
    Enea, Marco
    Macaluso, Fabio Salvatore
    Plaia, Antonella
    Bruno, Raffaele
    Gasbarrini, Antonio
    Bruno, Savino
    Craxi, Antonio
    Camma, Calogero
    [J]. DIGESTIVE AND LIVER DISEASE, 2014, 46 (10) : 936 - 942
  • [8] The Burden of Hepatitis C to the United States Medicare System in 2009: Descriptive and Economic Characteristics
    Rein, David B.
    Borton, Joshua
    Liffmann, Danielle K.
    Wittenborn, John S.
    [J]. HEPATOLOGY, 2016, 63 (04) : 1135 - 1144
  • [9] Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
    Younossi, Z. M.
    Park, H.
    Saab, S.
    Ahmed, A.
    Dieterich, D.
    Gordon, S. C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (06) : 544 - 563
  • [10] Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients
    Younossi, Zobair M.
    Singer, Mendel E.
    Mir, Heshaam M.
    Henry, Linda
    Hunt, Sharon
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (03) : 530 - 537
1